The role of vaccines in the COVID-19 pandemic: what have we learned?
F Krammer - Seminars in Immunopathology, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed …
Monoclonal antibody levels and protection from COVID-19
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
response has been rapid and effective, with many therapeutic monoclonal antibodies and …
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb)
titer against emerging variants of concern, an analogous pathway does not exist for …
titer against emerging variants of concern, an analogous pathway does not exist for …
A 9-year investigation of healthcare industry payments to pulmonologists in the United States
Rationale: The healthcare industry sometimes makes payments to physicians for
nonresearch and research purposes in the United States. Objectives: We aimed to evaluate …
nonresearch and research purposes in the United States. Objectives: We aimed to evaluate …
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171
H Zhang, J Zhou, H Chen, J Mao, Y Tang… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
This study is aimed to evaluate the safety, tolerability, and pharmacokinetics (PK), as well as
to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally …
to select an appropriate dosing regimen for the pivotal clinical trial of GST-HG171, an orally …
Mycophenolic Acid Exposure Determines Antibody Formation Following SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study
S Meziyerh, P Bouwmans, T van Gelder… - Clinical …, 2023 - Wiley Online Library
Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased
risk of severe COVID‐19 since a substantial number of individuals remain seronegative or …
risk of severe COVID‐19 since a substantial number of individuals remain seronegative or …
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People …
Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and
Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve …
Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve …
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a Phase 2/3 randomized, double-blind, placebo-controlled trial …
MG Ison, DF Weinstein, M Dobryanska… - Open Forum …, 2023 - academic.oup.com
Background The prevention of coronavirus disease 2019 (COVID-19) in vulnerable
populations is a global health priority. EVADE was a phase 2/3 multicenter, double-blind …
populations is a global health priority. EVADE was a phase 2/3 multicenter, double-blind …